<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016340</url>
  </required_header>
  <id_info>
    <org_study_id>MCS-5-TWN-a</org_study_id>
    <nct_id>NCT01016340</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of MCS-5 in Treating Male Oligoasthenospermia</brief_title>
  <acronym>MCS_MOS</acronym>
  <official_title>A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS-5 in Treating Male Oligoasthenospermia (MCS_MOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Ever Bio-Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Health Ever Bio-Tech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II randomized, double-blind, placebo-controlled study where eligible
      subfertile male subjects (age 20 years).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare changes in total motile sperm (TMS) between groups from baseline to 16 weeks after treatment</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Male Oligoasthenospermia</condition>
  <arm_group>
    <arm_group_label>MCS-5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1: MCS-5 5 mg/day for 16 weeks;Group 2: MCS-5 10 mg/day for 16 weeks;Group 3: MCS-5 20 mg/day for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 4: Placebo for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCS</intervention_name>
    <description>MCS-5 Softgel 5 mg</description>
    <arm_group_label>MCS-5</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male subjects who are 20 years old or older

          2. Subjects who are diagnosed as idiopathic oligoasthenospermia

          3. Subjects who have a normal baseline hormone profile

          4. Subjects who were not able to impregnate female partners in the past 12 months under
             an active and unprotected sexual life

          5. Subject's female partner has no endocrine or genital obstructive disorders and is
             capable of impregnation.

          6. Subjects who have an acceptable baseline liver function

          7. Subjects who have a normal baseline renal function.

        Exclusion Criteria:

          1. Subjects who have been diagnosed as male infertility for more than 5 years.

          2. Subjects who have a baseline semen white blood cell count of 1*106/mL.

          3. Subjects who have genital/seminal tract obstruction, infection, inflammation or
             anatomic abnormalities.

          4. Subjects whose female partner has been diagnosed as infertility of any kind.

          5. Male infertility that is associated with hormonal deficiency/imbalance, poor
             nutrition, congenital/chromosomal disorders, erectile dysfunction, or psychological
             disorders.

          6. Subjects who plan to undergo artificial insemination of any kind within the study
             period.

          7. Subjects who have been treated with chemotherapy, pelvic irradiation or major pelvic
             surgery

          8. Subjects who will undergo any invasive procedures within the study period

          9. Subjects who will undergo any chemotherapy or radiotherapy of any kind during the
             study period.

         10. Subjects who can not or are not willing to undergo the two-week wash-out period for
             any reasons.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fu-Feng Kuo</last_name>
    <phone>+886-2-25790062</phone>
    <email>ff.kuo@hebiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong-chiang Chang, M.D.</last_name>
      <email>hongchiangchang@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Hong-Chiang Chang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>November 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2009</study_first_posted>
  <last_update_submitted>December 13, 2011</last_update_submitted>
  <last_update_submitted_qc>December 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Male Oligoasthenospermia</keyword>
  <keyword>MCS</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

